Cancer Treatment Centers of America, Chicago. 410 — Zion, Illinois

Cancer Treatment Centers of America, Chicago. 410 is a clinical research site located in Zion, Illinois, United States 60099.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Cancer Treatment Centers of America, Chicago. 410 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma.

Sponsors: OncoC4, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Zion

Browse all research sites in Illinois · View every site in Zion

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Cancer Treatment Centers of America, Chicago. 410?

Cancer Treatment Centers of America, Chicago. 410 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Cancer Treatment Centers of America, Chicago. 410 conducted?

Cancer Treatment Centers of America, Chicago. 410 has 1 clinical trials on record, with 1 currently active. Their work covers Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma.

Is Cancer Treatment Centers of America, Chicago. 410 accredited by Crixeo Clinical Trials?

Cancer Treatment Centers of America, Chicago. 410 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Cancer Treatment Centers of America, Chicago. 410?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.